Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14748MR)

This product GTTS-WQ14748MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14748MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7825MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ1501MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ11396MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7518MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ2274MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ3118MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ3344MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ905MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW